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Creating novel enzymes by applied molecular evolution 
Adonis Skandalis, Lance P Encell and Lawrence A Loeb 
Recent molecular techniques have made it feasible to simulate 
evolutionary processes and apply in vitro selection to evolve 
enzymes with novel properties that may have potential benefits 
for medical and industrial applications. The characterization of 
such mutants has also provided new insights into how 
molecular structure determines enzyme function. 
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Introduction 
The survival of a cell or organism is dependent on an 
intricate web of chemical reactions that are catalyzed, 
with remarkable efficiency, by enzymes. Clearly, the 
optimization of enzymatic processes is of paramount 
importance to the survival of a cell. In the context of evo- 
lution, however, where the unit of natural selection is the 
organism and not individual proteins, each enzyme is 
optimized for a variety of parameters in addition to cat- 
alytic efficiency. The ‘perfect’ enzyme in the mind of a 
biochemist might be a highly active one with a turnover 
equal to the diffusion rate of the substrate. Having a more 
active enzyme in the cell, however, may not be advanta- 
geous. Such an enzyme could generate the progressive 
accumulation of individual metabolites which probably 
would be disadvantageous in the cell, where there are 
complex and interrelated metabolic signal pathways for 
maintaining homeostasis Stability, substrate specificity 
and flexibility to respond to regulatory elements are all 
parameters likely to shape the properties of enzymes 
found in living organisms. Mutants of many different 
enzymes may therefore have enhanced catalytic activity 
or altered substrate specificities, but these mutants might 
not have been selected under natural conditions. 
Another factor limiting the spectrum of mutant enzymes 
that can evolve naturally is historical contingency. It is 
thought that the majority of proteins evolved by gene 
duplication followed by sequential modification involving 
single amino acid substitutions [l]. The single amino acid 
replacements are then subjected to natural selection one 
at a time. For a mutation to be fixed, the resulting amino 
acid substitution must offer the cell a selective advantage 
over the wild-type protein, or at least be selectively 
neutral. Enzymatic enhancement or modulation by syner- 
gistic multiple mutations therefore cannot easily be 
explored in nature unless the mutations arise sequentially 
and each substitution results in a selective advantage. 
Often, however, an amino acid change that may be delete- 
rious by itself, may enhance activity in the presence of 
other mutations (examples will be presented in this 
review), implying that a large number of sequences encod- 
ing active proteins have not been, nor will they probably 
ever be, naturally evolved. 
The question of how many mutations a protein can toler- 
ate has occupied scientists for a long time, and the 
answer has important implications for evolution as well 
as for protein engineering. Nearly 30 years ago, Maynard- 
Smith [l] proposed that the density of functional pro- 
teins differing from the wild-type by one amino acid (one 
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amino acid sequence space) must be high in order for 
evolution to be possible. In the last 30 years, it has 
become clear that indeed proteins can retain function 
even with several substitutions within their active site, 
and that some of these variants have different properties 
than the wild-type form. 
Enzymes with enhanced or altered properties could 
benefit industry and medicine, and, at the same time, 
provide structure-function information about the protein. 
In industry, even marginal increases in enzyme stability or 
reaction rate could translate to significant cost savings. In 
medicine, gene therapy could benefit from the availability 
of certain mutant enzymes. Until recently, novel enzymes 
were obtained by searching for naturally occurring variants 
amongst exotic natural species that require a unique func- 
tion in order to survive. One example is the group of 
thermostable DNA polymerases discovered in microor- 
ganisms living in hot springs that have revolutionized bio- 
logical studies. These enzymes have made it feasible to 
dissect the human genome by amplifying single DNA 
molecules millions of times in vitro using the polymerase 
chain reaction (PCR). 
In contrast to the millenniums required for natural evolu- 
tion, it is now possible to generate mutant enzymes with 
altered properties rapidly in vitro using two general 
methodologies, summarized by the flow chart in 
Figure 1. One method involves the rational design of 
proteins by site-directed mutagenesis and the other uti- 
lizes random mutagenesis to mimic the evolutionary 
process. Random mutagenesis is also referred to as 
applied or directed evolution. This review will discuss 
these methods in protein engineering, with an emphasis 
on applied evolution of enzymes and the importance of 
genetic selection or high-throughput visual screening in 
obtaining mutants with the desired functions. In addition 
to reviewing current methods, we will discuss a few spe- 
cific examples of proteins that have been successfully 
evolved to carry out novel or enhanced functions for 
potential use in gene therapy. 
Rational protein design 
The simplest approach to altering the structure of an 
enzyme involves the change of codons within a DNA 
sequence by site-directed mutagenesis. Amino acids are 
substituted, one residue at a time, at positions believed to 
be important on the basis of information about the 
protein’s tertiary structure or previous mutagenesis experi- 
ments. The advantage of site-directed mutagenesis is that 
a site can be probed by specific substitutions. The results 
allow one to conclude whether a specific site can tolerate a 
specific change and to determine if changes alter the prop- 
erties of a particular variant. No selection or screening is 
required because the mutant protein can be assayed 
directly. Bias towards certain substitutions when using 
site-directed mutagenesis can be overcome by making 
many changes at many positions. It should be noted, 
however, that interpretation of the results may be diffi- 
cult. Loss of enzyme activity by certain substitutions does 
not indicate, by itself, that the replaced amino acid is 
directly involved in catalysis. 
Site-directed mutagenesis is essentially a reductionist’s 
approach which assumes that sufficient information can 
be obtained about amino acid interactions in a protein to 
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Table 1 Applied molecular evolution 
The number of potential variants (sequence space) of 
polymerase B for various numbers of amino acid changes. 
Number of amino acid changes Sequence space 
0 1’ 
1 6,061 
2 18,310,281 
3 36,760,940,821 
319 193’9 
‘Theoretical sequence space of polymerase p (319 amino acids) 
based on the number of residues (M) being substituted by the 19 alter- 
native amino acids. The number of sequences containing M amino acid 
substitutions is 19” x 319!1[(31 Q-M)!)!u!l. 
make it possible to predict the effect of specific substitu- 
tions. Unfortunately, our current understanding of amino 
acid interactions within proteins and their effect on func- 
tion is inadequate. Site-directed mutagenesis as a method 
to create new proteins with enhanced properties is there- 
fore extremely limited. Moreover, it is not feasible to 
analyze multiple mutations. As an example, in order to 
examine all the possible single mutants (one amino acid 
sequence space) in rat polymerase p (pol p; 319 amino 
acids), 6061 site-specific mutations would be required. If 
one was interested in all the possible mutants, including 
those with multiple substitutions, 19319 variants would 
have to be constructed (Table 1). 
Figure 2 
Applied molecular evolution circumvents the problems 
associated with rational design, as proteins are evolved for 
the characteristic(s) that we would like them to have. A 
detailed understanding of the changes necessary to reach 
such variants is not required. Instead of rationally design- 
ing proteins, powerful screening protocols can be used to 
sort out the enzyme with the desired properties from large 
libraries of mutant proteins. Spiegelman and Eigen [2,3] 
were among the early pioneers to use applied molecular 
evolution on Qb bacteriophage. The first in vitro evolution 
of DNA sequences involved insertion of random oligonu- 
cleotides followed by genetic selection [4]. We will discuss 
the specific approaches that have been used in applied 
evolution by reviewing first the methodologies used to 
generate molecular diversity (libraries of mutants) and 
then the methodologies used in the screening of these 
libraries for altered enzymes (Figure 2). 
Methods for generating random diversity 
The introduction of random mutations into a gene or gene 
segment is analogous to the natural processes that are 
operative during evolution, but the yield of mutations can 
be much higher. Mutations can be introduced throughout 
the coding region of a gene, or they can be confined to 
specific segments. In contrast to site-directed mutagene- 
sis, a prior knowledge of the structure of the protein is not 
required. An overview of the methodologies to be pre- 
sented in this review is shown in Figure 2. 
The creation of random libraries by applied 
molecular evolution. A gene target can be 
randomized by one of several methods, 
followed by ligation of the library into a vector 
backbone and transformation into an 
appropriate strain of fschefichia co/i for 
selection/screening. 
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Amino acid substitution by mutagenic 
processes 
Chemical damage 
Damage to nucleotide residues in DNA frequently results 
in their misincorporation during in a&o DNA synthesis or 
during DNA replication in vz’vo. This approach has been 
extensively utilized to produce a small number of muta- 
tions in a gene. An example is the use of nitrous acid 
(HNO,) for inducing base deaminations. HN02-damaged 
DNA can be subjected to PCR amplification to introduce 
mutations. This method has been quantitated to consis- 
tently yield -1 substitution per 500 bases [5,6]. Other 
chemical reactants used include: formic acid, sodium 
bisulfate, hydrazine and dimethylsulfate [7]. The region 
for mutagenesis can be limited by replacing a segment of 
the gene with a corresponding damaged sequence. 
Mutagenic PCR 
The intrinsic mutation frequency of PCR, in the absence 
of prior treatment with DNA damaging agents, may 
produce sufficient numbers of mutations, by itself, to 
establish a library. Standard PCR using Tap polymerase 
consistently yields -1 substitution per 1000 bases and has 
been used with success to create mutant libraries [8]. 
Replacing magnesium with manganese as the divalent 
cation can lead to an increase in mutation frequencies of as 
much as 0.66% [9,10]. Dnase I digestion prior to sexual 
PCR methods, which will be discussed later, is also muta- 
genic. Mutation frequencies between 0.05 and 0.70% have 
been reported, depending on the exact conditions used 
[ll,lZ]. Another approach that has been taken is to incor- 
porate known mutagenic nucleoside analogs into the pool 
of normal deoxynucleoside triphosphates (dNTPs) during 
PCR. S-oxo-substituted nucleosides including 8-oxodG 
have been used for this type of library construction, and 
have yielded libraries containing an array of transition 
mutations [13]. Additionally, biased pools of normal 
dNTPs can lead to the introduction of mutations [14]. In 
such protocols, incorrect bases are incorporated at a much 
slower rate than the normal base, but they can be ample 
for generating libraries of mutants. Deoxyinosine triphos- 
phate (dITP) has been used to restore the efficiency of 
the PCR when a particular dNTP is absent [15]. Under 
these conditions, dITP gets incorporated in place of the 
missing normal dNTP. Interestingly, the recent produc- 
tion of error-prone mutant Taq DNA polymerases by 
random sequence mutagenesis [16] should provide a new 
set of mutant enzymes for increased mutagenesis in PCR 
reactions. Although these approaches have been success- 
ful, there are two major disadvantages. First, the fre- 
quency of mutations produced within a short gene 
segment is low and thus it is difficult to obtain multiple 
mutations within a catalytic site. Second, the introduction 
of mutations is not completely random. In other words, 
‘hot-spots’ for damage/incorporation are likely to produce 
a non-random distribution of mutations. 
DNA shuffling (sexual PCR) 
DNA shuffling utilizes general homologous recombina- 
tion in aitro. The approach involves the digestion of 
homologous yet diverse (mutagenized or from different 
species) target sequences by Dnase I and yields a pool of 
DNA fragments that can then be reassembled into a 
hybrid full-length sequence by mutagenic, primerless 
PCR [ll]. The fragments prime each other on the basis of 
their homology and recombination occurs when frag- 
ments from one copy of a gene prime on another copy, 
causing a template switch. The method can be used in 
combination with other in vitro evolution techniques to 
generate hybrid molecules containing segments with dif- 
ferent mutations. At the same time, irrelevant or deleteri- 
ous mutations can be eliminated by back-crossing 
because the methodology can segregate mutations; muta- 
tions that do not contribute to the phenotype do not 
persist. DNA shuffling has been used successfully for the 
applied evolution of several proteins, including p-lacta- 
mase [ 111, green fluorescent protein (GFP) [ 171, p-fucosi- 
dase [18] and an arsenate detoxification operon [19]. 
Mutator Escherichia coli strains 
An Escheticha co/i strain lacking mismatch repair (mutS), 
oxo-GTP repair (mutT) and 3’-5’ exonuclease activity of 
DNA pol III (mutD) has been shown to have a 5000-fold 
higher mutation rate than wild-type [ZO]. This strain, or a 
variety of other mutator strains, can be used to introduce 
mutations into plasmids and thus generate libraries of 
mutant genes. In principle, mutator strains can serve as a 
host to mediate the continuous selection for mutations 
with desired characteristics. 
Random oligonucleotides 
The use of degenerate DNA oligonucleotides provides a 
facile method of generating molecular diversity. The 
basic concept is to replace a portion of a plasmid-borne 
gene encoding an enzyme with a ‘randomized’ oligonu- 
cleotide containing all four nucleotides at specified posi- 
tions. The entire population of recombinant plasmids 
contains random substitutions at the designated positions, 
whereas individual isolates contain unique sequences. 
The degree of randomization, and consequently the 
average number of amino acid substitutions per isolate, is 
an important parameter that can be controlled by varying 
the ratio of the wild-type base to the other three bases. 
Bias towards the wild-type nucleotide limits the number 
of substitutions produced within a given molecule. The 
methodology of generating the oligonucleotides for this 
technique has been reviewed extensively [Zl-231. The 
approach was first utihzed to introduce random substitu- 
tions into the promoter region of the tetracycline resis- 
tance gene [4] and then into the active site of p-lactamase 
[24]. Since these initial studies, random oligonucleotides 
have been used to study a variety of enzymes, some of 
which will be discussed in detail below. 
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Figure 3 
The frequency (expressed as % total) of 
amino acid substitutions in ‘unselected’ and 
‘selected’ AGT mutants (L.P.E., M.M. Coates 
and L.A.L., unpublished observations). 34 
clones were sequenced from the unselected 
human AGT library containing random 
mutations amongst amino acids 150-l 72 and 
it was determined that on average there were 
8 amino acid substitutions per mutant. 111 
clones were sequenced from the N-methyl-N’- 
nitro-N-nitrosoguanidine (MNNG)-selected 
library and it was found that there were on 
average 3 amino acid substitutions per 
mutant. 
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Genetic selection 
Often the limiting factor in evolving a protein is not the 
method used to generate a library of mutants, but the 
approach used to identify the active variants of interest. In 
order to select the small subset of functional enzymes 
from the large pool of variants in a library, an efficient 
screening system is necessary. The most powerful tech- 
nique for identifying functional viable mutants is positive 
genetic selection. An illustration of the power of this 
approach is the genetic complementation system for DNA 
polymerases [Z]. The genetic selection is based on a bac- 
terial strain that is temperature sensitive for DNA poly- 
merase I (pol I). This strain is unable to grow at the 
non-permissive temperature of 37°C unless a plasmid 
encoding a functional exogenous polymerase is intro- 
duced. Several DNA polymerases have been shown to 
complement the pol I temperature sensitivity, including 
mammalian pol p, HIV reverse transcriptase (HIV RT) 
[26] and Taq polymerase [27]. 
Pol p is involved in DNA repair and its small size (39 kDa) 
and lack of exonucleolytic function have made it a model 
for studying polymerases [28]. As a result, a wealth of 
structural information exists that assists in establishing the 
functional domains of the polymerase and, in return, 
protein engineering studies help validate the structural 
studies. A pool of 10,000 pol p mutant clones generated by 
chemical mutagenesis (HNO,) of 248 base pairs and a 
pool of 7000 mutants generated by mutagenic (Mn2+) 
PCR of 89 base pairs were tested by the genetic comple- 
mentation assay [5,25,29]. The survivors were subjected to 
a screen for identifying polymerases with lower replication 
fidelity to yield 13 low fidelity mutant polymerases. The 
mutants sequenced had only single amino acid changes. 
The same genetic selection was used to identify active 
mutant pol p from a library of 100,000 mutants generated 
by random mutagenesis of 15 nucleotides coding for the 
dNTP binding domain of the polymerase. Only 4% of the 
mutants were found to be active in complementing pol I 
function (A.S. and L.A.L., unpublished observations). 
Further analysis by direct assay of the individual mutants 
identified polymerases with both lower and higher fidelity 
than that of wild-type. Each of these mutants contained 
single amino acid changes. 
Another example of a powerful selection scheme involves 
human 06-alkylguanine-DNA alkyltransferase (AGT). 
Using a bacterial strain lacking alkyltransferase, large 
libraries of AGT mutants have been screened for those 
enabling the cells to survive treatment with alkylating 
agents. Figure 3 shows the effect that this type of genetic 
selection has on the extent of amino acid substitution com- 
pared to the unselected library. The figure shows that an 
AGT library contained prior to selection eight amino acid 
substitutions per randomized segment. Following genetic 
selection, the collection of mutants conferring resistance to 
alkylating agents had on average only three amino acid sub- 
stitutions (L.P.E., M.M. Coates, and L.A.L, unpublished 
observations). This type of shift provides a valuable measure 
of the quality of the selection scheme. Most importantly, it 
also provides information about the amino acid substitutions 
that lead to loss of function. This is a unique property of the 
random oligonucleotide mutagenesis method and it assists 
greatly in identifying critical residues [27]. 
Positive selection for drug resistance was also used in the 
selection of p-lactamase mutants after extensive rounds of 
DNA shuffling [ll]. The P-lactamase gene TEM-2 pro- 
vides weak resistance to the antibiotic cefotaxime. Previ- 
ous attempts to generate and identify mutants that 
provided enhanced resistance to the antibiotic yielded a 
modest result of a 16-fold increase [24]. Three rounds of 
DNA shuffling and two rounds of back-crossing with an 
increasing concentration of the cefotaxime yielded mutants 
that were as much as 32,000-fold more resistant than the 
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wild-type. The highly resistant mutants identified had at 
least six amino acid changes. The authors note that high 
resistance can only be achieved by altering more than one 
gene region [11,30]. DNA shuffling can also be applied to 
gene families. By shuffling homologous genes from differ- 
ent species, one can take advantage of genetic diversity 
that has taken billions of years to evolve. Crameri etal. [31] 
found that an eightfold increase in moxalactam resistance 
compared to wild-type could be achieved from single 
libraries of shuffled microbial class C cephalosphorinase 
genes that are >50% identical at the DNA sequence level. 
The best clone obtained when four microbial homologs 
were shuffled, however, showed as high as a 540-fold 
increase in resistance compared to the wild-type. 
Visual screening 
Although genetic selection is most efficacious for sorting 
large libraries of mutants, high-throughput visual screening 
has also lead to the identification of mutants with signifi- 
cantly enhanced functions. This type of screening was 
used in bacteria to screen for increased whole cell fluores- 
cence by bacteria expressing GFP [17]. GFP variants were 
generated by protein shuffling and approximately 10,000 
bacterial colonies were screened per cycle, from which the 
40 brightest colonies were picked. After three rounds of 
shuffling, a mutant with three amino acid substitutions that 
had a 45-fold increase in fluorescence was isolated. This 
increase was attributed to better solubility in bacterial cells 
rather than changes in emission and excitation maxima. 
Visual screening was also used in the applied evolution of a 
novel para-nitrobenzyl (pNB) esterase [8]. Such an enzy- 
matic function is highly desirable for the industrial manu- 
facture of antibiotics, as current methods generate 
significant solvent and zinc waste. The substrate of the 
parent enzyme was unknown but it exhibited weak pNB 
esterase activity in aqueous solutions. The industrial appli- 
cation frequently requires activity in an organic solvent 
environment, however. After each of four cycles of muta- 
genic PCR, 1000-7000 bacterial colonies were screened for 
esterase activity using an artificial substrate that generates 
calorimetric signals. One additional round of DNA shuf- 
fling produced a five amino acid change mutant that had a 
30-fold increase in activity in organic solvent. 
A remarkable screening scheme has recently been used to 
detect nonfunctional but full-length poly(ADPribose) 
polymerase (PARP) mutants in order to study inactivating 
mutations of the gene [32]. PARP is a very complex, mul- 
tifunctional nuclear zinc-finger protein which is involved 
in the response of cells to DNA strand breaks. A library of 
PARP variants with mutations at the catalytic domain was 
generated by PCR and introduced into E. co/i. The bacter- 
ial colonies were then replica plated onto nitrocellulose 
and screened for function using an activity assay. It was 
determined that 2% of the colonies carried inactive PARP. 
The same blot was immunostained in order to confirm full 
length product and exclude truncating mutations and then 
qualifying genes were sequenced. The data are very 
useful for structure-function analysis, but the authors 
point out that the same screen can be used for identifying 
rescue mutations, generating libraries of inactive PARP 
mutants, or for gain-of-function mutations. Indeed a 
PARP mutant with a ninefold increase in k,,, value has 
been identified using a similar methodology [33]. 
Generating unique enzymes for gene therapy 
The in vitro evolution of new and unique enzymes could 
have direct implications in gene therapy for treating 
human cancers. A major goal of cancer gene therapy is to 
introduce lethal genes into tumor cells. Among the candi- 
date genes would be those that render tumor cells 
uniquely sensitive to chemotherapeutic agents. The gen- 
eration of mutant drug-activating enzymes with enhanced 
catalytic activity could accomplish this. The enzyme 
herpes simplex virus (HSV) thymidine kinase (TK), which 
is currently in clinical protocols for gene therapy, falls into 
this category and is discussed below. A more immediately 
achievable goal in cancer gene therapy, however, may be 
the introduction of genes expressing mutant proteins into 
normal tissues in order to protect them against the drugs 
currently being used in cancer therapy. Because myelo- 
suppression often dictates the dosages used for many 
chemotherapeutic agents, enhanced protection of marrow 
cells could allow increased doses of many effective 
chemotherapeutic agents to be used. Bone-marrow stem 
cells expressing the protective enzyme should have a 
selective advantage and would be able to repopulate the 
marrow. AGT presents an example for which this type of 
approach could be used and the wild-type form has been 
proposed for clinical protocols. The production of mutant 
HSV TK and AGT with enhanced activities may offer 
unique advantages over wild-type forms. 
HSV thymidine kinase 
Human TK exhibits a high stringency in substrate selec- 
tion, as it catalyzes the phosphorylation of thymidine and 
only a limited number of related analogs. In contrast, HSV 
TK is able to efficiently phosphorylate a variety of 
nucleotide substrates, including the guanine analogs gan- 
cyclovir and acyclovir. These analogs lack a 3’-hydroxyl ter- 
minus, terminate DNA synthesis, and prevent both viral 
and host cell replications [34]. One way to kill cancers 
selectively is to introduce HSV TK into cancer cells and 
then administer gancyclovir systemically. HSV TK has 
been introduced to tumors in animals by a variety of 
methods, and the tumors regress following treatment of the 
animals with acyclovir or gancyclovir [35-381. The power 
of this method could be enhanced by identifying HSV TK 
mutants that phosphorylate analogs preferentially. 
We have carried out remodeling of the nucleotide binding 
site of HSV TK by random sequence mutagenesis in 
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06.Alkylguanine-DNA HSV Thymidine 
alkyltransferase kinase 
Amino acid substitutions in (a) human AGT 
mutants that were selected by resistance to 
three rounds of treatment with MNNG (L.P.E., 
M.M. Coates and L.A.L., unpublished 
observations); (b) TK mutants selected by the 
ability to complement TK deficient E. co/i and 
allow growth on agar containing 5’- 
fluorodeoxyuridine [23). For both (a) and (b), 
the one-letter code for amino acids is used. 
The wild-type sequence is shown below the 
solid line and the substitutions observed at 
each position and their frequency are 
indicated above each site. Phylogenetically 
conserved residues are boxed and, in the 
case of AGT, those that are invariant in 
mammals are underscored. 
attempts to create such mutants. Active mutant HSV TKs 
were identified by genetic complementation of an 8. co/i 
strain lacking thymidine kinase [39]. The mutability of 
individual amino acids was analyzed by substituting a 
long contiguous nucleotide stretch with a random 
sequence biased towards wild-type sequence. Approxi- 
mately 240 mutants were screened and 34% conferred TK 
activity. Certain residues appear to be highly conserved, 
while other positions allow a variety of changes (Figure 
4b). We thereby identified amino acids that tolerate only 
a limited number of substitutions and completely ran- 
domized their codons. Thereafter active mutants were 
subjected to negative genetic selection to determine 
which members of the library conferred preferential 
killing by specific nucleoside analogs. Using this 
approach, a series of mutant HSV TKs that selectively 
phosphorylate gancyclovir and/or acyclovir were obtained 
[40]. Six codons were targeted with this technique and a 
library was obtained of more than lo6 E. coli transfor- 
mants; 426 of these were active as measured by genetic 
complementation. These mutants were analyzed for 
enhanced killing by gancyclovir and acyclovir. Of the 
active mutants, 26 conferred enhanced sensitivity to gan- 
cyclovir, 54 to acyclovir and 6 to both analogs. Ten of the 
mutants that were sequenced contain three to six amino 
acid replacements within the nucleoside binding site; 
notably, these combinations of substitutions would proba- 
bly not have been chosen by rational remodeling of the 
active site. Hamster cells transfected with one of the 
mutants containing four substitutions, IlelbO+Leu, 
Phel61+Leu, Ala168+Val, Leul69+Met, were more 
than 43-fold and ZO-fold more sensitive to gancyclovir and 
acyclovir, respectively, than cells expressing equivalent 
amounts of the wild type HSV TK. 
HSV TK mutants obtained by random mutagenesis have 
also been studied for altered thermal stability [41]. One 
mutant in particular has been found that is more stable at 
42°C than wild-type when cell extracts were assayed for 
TK activity. Using purified proteins, it was found that this 
mutant lost only 10% of its activity over 4.5 min during a 
pre-incubation at 42°C. In contrast, wild-type HSV TK lost 
> 85% activity under the same conditions. This mutant 
contained three amino acid substitutions. Interestingly, 
none of the single or double mutants tested at these posi- 
tions resulted in mutants with increased thermal stability. 
06-Alkylguanine-DNA alkyltransferase 
AGT is a suicide enzyme that repairs alkylation damage at 
the 06 position of guanine in DNA. (The term @-alkylgua- 
nine-DNA alkyltransferase, shortened to alkyltransferase 
and abbreviated MGMT also refers to this protein.) 06- 
alkylguanine is one of the major cytotoxic and mutagenic 
lesions produced in DNA by a variety of alkylating agents, 
including chemotherapeutic nitrosoureas. AGT excises 
alkyl groups from the 06 position of guanine, and less effi- 
ciently from the O‘r position of thymine, to restore the 
nucleic acid’s native structure [42,43]. Alkylating agents are 
used therapeutically for the treatment of many cancers and 
with these agents the limiting factor in dose escalation is 
myelosuppression. The sensitivity of the bone marrow to 
these treatments is, in part, due to inherently low levels of 
AGT in these cells. Overexpression of wild-type AGT in 
hematopoietic stem cells via retrovirus-mediated gene 
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transfer has been shown to protect both murine [44] and 
human [45] bone marrow cells from the clinically used alky- 
lating agent 1,3-bis(Z-chloroethyl)-1-nitrosourea (BCNU). 
These studies demonstrate the feasibility of expressing 
AGT in bone marrow for protection against myelosuppres- 
sion induced by alkylating agents. Random mutagenesis 
was used to create libraries of AGT mutants with the goal 
of evolving new proteins with activities and characteristics 
that are enhanced over wild-type. Mutants were expressed 
in alkyltransferase-deficient E. coli and active clones were 
selected according to their ability to survive a stringent 
treatment with the toxic methylating agent N-methyl-N’- 
nitro-N-nitrosoguanidine (MNNG). Upon sequencing sur- 
vivors, it was discovered that certain AGT residues were 
highly substitutable, while others were resistant to change 
(Figure 4a). One library contained a mutant that offers bac- 
teria approximately tenfold increased protection against 
MNNG compared to wild-type [46]. @-Benzylguanine 
(BG) is a competitive inhibitor of AGT, and is currently in 
phase II clinical trials for sensitizing tumors to treatment 
with therapeutic alkylating agents [47]. The mutant with 
increased resistance to MNNG remains sensitive to BG. 
We have evolved new AGT proteins that are resistant to 
this inhibitor, however. By selecting mutants that are resis- 
tant to MNNG and BG, we have created a panel of BG- 
resistant alkyltranferases that are potential candidates for 
gene therapy to prevent myelosuppression in patients 
receiving the combination therapy of alkylating agents and 
BG [48] (L.P.E., M.M. Coates and L.A.L, unpublished 
observations). Interestingly, one of these mutants exhibits 
improved protection against MNNG. This mutant contains 
only a single amino acid change, yet nature has not selected 
the protein already. In contrast, the mutants that are the 
most resistant to BG all contain from three to eight amino 
acid substitutions. Clearly a mutant containing eight amino 
acid substitutions would have an extremely slim chance of 
being selected naturally. 
Recently, the entire human AGT gene has been random- 
ized by DNA shuffling (F.C. Christians, G. Dawes and 
W.P.C. Stemmer, unpublished observations). In these 
studies, the human gene was fragmented by Dnase I 
digestion (as described above) and oligonucleotides from 
four other mammalian alkyltransferases were doped into 
the reassembly reaction. Active mutants were selected 
from the resulting library as described above. The most 
active mutant selected showed nearly tenfold more resis- 
tance to MNNG than any other mutant found to date. 
This new mutant contains seven amino acids changes, all 
at positions not previously examined. 
Glutathione S-transferase 
Glutathione S-transferase (GST) detoxifies a broad range 
of electrophilic species capable of reacting with and dam- 
aging cellular macromolecules. Overexpression of this 
enzyme has been shown to protect cells from a variety of 
structurally different chemotherapeutic agents, including 
the alkylating agents used in treatment of brain tumors, 
and mechlorethamine used in the treatment of lym- 
phomas. Nature evolved GST to metabolize structurally 
diverse compounds; however, random oligo mutagenesis 
techniques have been used to increase the specificity of 
the enzyme for a single agent, mechlorethamine [49]. In 
these studies, bacteria harboring a random library of GST 
active site mutants were subjected to eight rounds of 
treatment with increasing concentrations of mechlor- 
ethamine. Mutant enzymes were isolated from surviving 
bacteria and were shown to have up to a tenfold increase 
in resistance to the alkylating agent compared to wild-type 
GST. The most resistant mutants contained three amino 
acid substitutions. All three changes in the same mutant 
appeared to be required for optimal resistance, as none of 
the single mutants tested were found to offer resistance 
greater than that of wild-type GST. The mutants, which 
are candidates for gene therapy for protecting bone 
marrow, again demonstrate that multiple mutations 
provide optimum effect. This example also suggests that 
GST could be tailored to detoxify a variety of other drugs 
simply by using the drug of interest for the selection 
process. The approach could be applied to other drug 
metabolizing enzymes such as cytochromes P450 which 
have also evolved to display wide substrate specificities 
that could be focused and amplified by directed evolution. 
Conclusions 
The proteins described above represent only a few exam- 
ples of applied molecular evolution. Many other proteins 
have been evolved in vitro by methods described here. It 
appears that within the eight amino acid sequence space of 
all the proteins tested to date, mutants exist that have 
remarkably diverse properties not present in the wild-type. 
A sequence space of this size contains over 10z5 variants for 
an average protein. In Table 2 we list certain characteris- 
tics of some of the libraries that have been screened by our 
laboratory using genetic selection assays. The size of these 
libraries is nowhere near that of the sequence space. 
Success in identifying proteins with new properties may 
be indicative of the fact that the sequence space of pro- 
teins is densely packed with functional variants as 
Maynard-Smith predicted [l]. This conclusion is further 
supported by the results of experiments using visual 
screening, in which the library size is limited to 104. In our 
quest for creating proteins with more extraordinary enzy- 
matic activities, it is our imagination for designing selec- 
tion assays that may ultimately limit what can be achieved. 
The results described in this review also demonstrate that 
the properties leading to the selection of an enzyme are not 
always apparent, and that very desirable properties for an 
enzyme may be relatively easy to obtain by applied evolu- 
tion but are not adaptive and therefore not selected in an 
organism. Pol B mutants that had a single amino acid 
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Table 2 
The size of libraries generated by random oligonucleotlde 
mutagenesis and the number of active mutants recovered. 
Target gene Clones examined Active mutants Reference 
HSV TK (sites 3 & 4) 1.1 x 106 426 [401 
HIV RT 1.2 x 104 1400 [261 
AGT 6.5 x 1 O6 37 [481 
Tag DNA pot I 1.2x 106 81 [501 
change and dramatically different fidelity were identified; 
the mutants might have served as a substrates for natural 
selection, but, for unknown reasons, they were not 
selected. It is intriguing that a higher fidelity mutant would 
not have been selected and fixed. On the other hand, mul- 
tiple mutations were required for producing the enzymatic 
specificities required by the selections in the case of p-lac- 
tamase, para-nitrobenzyl esterase, AGT, HSV TK and 
GST. Such events are very rare in nature and therefore it 
would be hard to evolve such enzymatic activities naturally. 
Increased catalytic activity is not the only goal that can 
be achieved by applied evolution. As was demonstrated 
by the HSV TK and pol p studies, it is possible to iden- 
tify enzymes with altered fidelity. Such enzymes could 
have a role in gene therapy. Lower fidelity pol p could be 
used to sensitize tumors to DNA-damaging therapeutic 
agents as ablative gene therapy. Alternatively, a high 
fidelity pol p may have potential for protecting bone 
marrow as in the case of the previously mentioned gene 
therapy candidates. Protein stability has also been a 
target of applied molecular evolution as was the case with 
GFP and para-nitrobenzyl esterase [8,17]. Prior to 
protein engineering tools, we could only wonder how 
certain residues contribute to stability and function, and 
it is of particular interest that in certain cases the substi- 
tutions responsible for increased stability can be com- 
bined to show an additive effect [8]. 
Summary 
The applied evolution of proteins, specifically enzymes, 
has become a basic tool for many different disciplines of 
science. With little or no knowledge of the three-dimen- 
sional structure of a given enzyme, the sequence space of 
entire genes or specific regions can be analyzed using the 
methods described in/this review. The boundaries of this 
approach are defined by the imagination and the ability to 
devise a clever selection strategy to identify the functions 
of interest in a novel enzyme. So far, applied molecular evo- 
lution has produced new enzymes with enhanced proper- 
ties or altered substrate specificities that make them 
desirable for both industrial and medical applications. The 
outcome of these studies can also provide structure-func- 
tion information about the enzyme being studied. 
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